Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Billions of dollars in potential awards, a new map for antitrust litigation, and what many say is a likely spot on the Supreme Court docket; Empagran v. F. Hoffman-LaRoche has it all. What could it mean for U.S. pharmaceutical (and other) companies? “Corporations in this country and all over the world are really scared of this,” says Paul Gallagher, a Washington D.C.-based Cohen, Milstein, Hausfeld & Toll partner who serves as lead plaintiffs counsel in the case.
A class action filed by foreign vitamin buyers, the suit is the latest round in the already epic litigation over vitamin price fixing. The cases stem from a Department of Justice criminal investigation that began in the mid-1990s and have yielded more than $1 billion in fines against a cartel of multinational pharmaceutical giants.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
When we consider how the use of AI affects legal PR and communications, we have to look at it as an industrywide global phenomenon. A recent online conference provided an overview of the latest AI trends in public relations, and specifically, the impact of AI on communications. Here are some of the key points and takeaways from several of the speakers, who provided current best practices, tips, concerns and case studies.
On Aug. 9, 2023, Gov. Kathy Hochul introduced New York's inaugural comprehensive cybersecurity strategy. In sum, the plan aims to update government networks, bolster county-level digital defenses, and regulate critical infrastructure.